Literature DB >> 11035096

Memory-type CD8+ T cells protect IL-2 receptor alpha-deficient mice from systemic infection with herpes simplex virus type 2.

H Tsunobuchi1, H Nishimura, F Goshima, T Daikoku, Y Nishiyama, Y Yoshikai.   

Abstract

IL-2Ralpha-deficient (IL-2Ralpha(-/-)) mice exhibit an impaired activation-induced cell death for T cells and develop abnormal T cell activation with age. In our study, we found that IL-2Ralpha(-/-) mice at the age of 5 wk contained an increased number of CD44(+)CD69(-)CD8(+) T cells in lymph nodes, which expressed a high intensity of IL-2Rbeta and vigorously proliferated in response to a high dose of IL-15 or IL-2. The T cells produced a large amount of IFN-gamma in response to IL-15 plus IL-12 in a TCR-independent bystander manner. When IL-2Ralpha(-/-) mice were inoculated i.p. with HSV type 2 (HSV-2) 186 strain, they showed resistance to the infection accompanied by an increased level of serum IL-15. The depletion of CD8(+) T cells by in vivo administration of anti-CD8 mAb rendered IL-2Ralpha(-/-) mice susceptible to HSV-2-induced lethality. These results suggest that memory-type CD8(+) T cells play a novel role in the protection against HSV-2 infection in IL-2Ralpha(-/-) mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035096     DOI: 10.4049/jimmunol.165.8.4552

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use.

Authors:  Pin-Yu Perera; Jack H Lichy; Thomas A Waldmann; Liyanage P Perera
Journal:  Microbes Infect       Date:  2011-10-25       Impact factor: 2.700

2.  IL-2: a two-faced master regulator of autoimmunity.

Authors:  Rahul Sharma; Shu Man Fu; Shyr-Te Ju
Journal:  J Autoimmun       Date:  2011-02-01       Impact factor: 7.094

3.  IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25.

Authors:  Sven Létourneau; Ester M M van Leeuwen; Carsten Krieg; Chris Martin; Giuseppe Pantaleo; Jonathan Sprent; Charles D Surh; Onur Boyman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

4.  IL-36γ induces a transient HSV-2 resistant environment that protects against genital disease and pathogenesis.

Authors:  Jameson K Gardner; Melissa M Herbst-Kralovetz
Journal:  Cytokine       Date:  2018-08-15       Impact factor: 3.861

Review 5.  The role of interleukin-2 during homeostasis and activation of the immune system.

Authors:  Onur Boyman; Jonathan Sprent
Journal:  Nat Rev Immunol       Date:  2012-02-17       Impact factor: 53.106

6.  Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.

Authors:  Carsten Krieg; Sven Létourneau; Giuseppe Pantaleo; Onur Boyman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

7.  Role of interleukin 15 in colitis induced by dextran sulphate sodium in mice.

Authors:  K Yoshihara; T Yajima; C Kubo; Y Yoshikai
Journal:  Gut       Date:  2005-09-14       Impact factor: 23.059

8.  Bioluminescence imaging reveals systemic dissemination of herpes simplex virus type 1 in the absence of interferon receptors.

Authors:  Gary D Luker; Julie L Prior; Jiling Song; Christina M Pica; David A Leib
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Intraepithelial gammadelta T cells may bridge a gap between innate immunity and acquired immunity to herpes simplex virus type 2.

Authors:  Hitoshi Nishimura; Toshiki Yajima; Yoshiko Kagimoto; Mutsuhiro Ohata; Taketo Watase; Kenji Kishihara; Fumi Goshima; Yukihiro Nishiyama; Yasunobu Yoshikai
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection.

Authors:  Ali A Ashkar; Kenneth L Rosenthal
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.